ANGELALIGN (06699.HK) Latest News & Headlines | Longbridge

© 2026 Longbridge｜Terms of Service Privacy Policy

M Stanley Raises ANGELALIGN TP to HKD105, Maintains Equalweight Rating
AASTOCKS News·16 hours ago
- Morgan Stanley adjusted ANGELALIGN's 2026 to 2028 revenue forecasts upward by about 4% and revised EPS forecasts by -1%, +6% and +6% respectively. - The adjustments reflect strong domestic and overseas sales momentum, higher litigation and equity incentive expenses, and improved working capital efficiency. - Morgan Stanley raised ANGELALIGN's target price by 11% to HKD 105 while maintaining an Equalweight rating.
06699+0.42%
Angelalign Technology jumps nearly 8% as first-half profit soars 86%
HK Stock Market Update·1 day ago, 03:34 AM
06699+0.42%
Angelalign Technology (SEHK:6699) Is Getting Fresh Attention, What Is The Market Weighing?
Simplywall·2 days ago, 04:21 PM
- Angelalign Technology reported half year 2026 earnings with sales of US$ 230.7 million and net income of US$ 27.25 million, alongside a strong recent share price rebound. - The company trades at a high price-to-earnings ratio of 69x, significantly exceeding the peer group average of 28.8x and the wider industry average of 16.8x. - A discounted cash flow model estimates fair value at HK$ 82.07 per share compared to the trading price of HK$ 90, indicating the stock may be overvalued.
06699+0.42%
Angelalign Technology declares interim dividend of HKD 0.47 per share
PUBT·2 days ago, 11:33 AM
- Angelalign Technology declared an interim dividend of HKD 0.47 per share for the six months ended June 30, 2026. - The shares will trade ex-dividend on Sept. 10, 2026, with the record date set for Sept. 16, 2026. - The dividend payment will be distributed to shareholders on Sept. 25, 2026.
06699+0.42%
Angelalign Technology: Revenue up 42.9% and net profit up 79.6% year-over-year, with global markets achieving profitability
Quartr·2 days ago, 11:06 AM
- Angelalign Technology reported its financial results with revenue growing 42.9 % year-over-year to USD230.7 million and net profit rising 79.6 % to USD25.5 million. - Global markets contributed over half of the case volume and revenue while achieving profitability alongside strong growth in the Chinese mainland segment. - The company declared both interim and special dividends following its solid financial performance.
06699+0.42%
Angelalign FY26 H1 net profit climbs 79.6% to USD 25.5 million; revenue rises 42.9% to USD 230.7 million
PUBT·2 days ago, 11:05 AM
- Angelalign reported its FY26 H1 financial results, showing a net profit of USD 25.5 million and revenue of USD 230.7 million. - Clear aligner case volume increased by 40.2% to 316,609, with global markets contributing significantly to the growth. - The company declared an interim dividend of HKD 0.47 per share and a special dividend of HKD 4.10 per share.
06699+0.42%
The Value Chain Shift: From IP Commercialization to Legacy Capital
Global Report·Aug 25 at 10:12 AM
- The Hong Kong stock market is undergoing a structural divergence driven by core intellectual property, global supply chains, and platform effects. - Companies like Everest Medicines and Weichai Power achieved robust financial growth in 2026 by successfully commercializing products and expanding global networks. - Capital and traditional sectors are actively rebalancing their portfolios toward technology innovation while navigating ongoing asset cycles.
06699+0.42%02338-4.11%
The Hong Kong Hustle: What a Ragtag Group of Equities Tells Us About Market Survival
Global Report·Aug 18 at 09:44 AM
- The article analyzes the survival rules of ten diverse companies in the Hong Kong stock market, emphasizing that the current market demands solid financial performance and execution over empty concepts. - Swire Properties achieved a 23% surge in mainland retail tenant sales and acquired Beijing INDIGO Phase II, while ZTO Express delivered over 8.5 billion parcels and 20 billion in net profit in the first quarter of 2025. - Conversely, FTG saw net losses expand by over 700% by the end of 2025, and Haitong International suffered heavy floating losses despite massive capital injections, illustrating that the market tolerates zero illusions.
01972+1.31%01836-1.68%
09:39 ETAngelaligner złoży apelację od wyroku chińskiego sądu w sprawie rozwiązania dotyczącego ekstrakcji zębów przedtrzonowych; wyrok nie ma wpływu na interesy klientów
prnewswire·Aug 13 at 01:41 PM
- Angelalign Technology Inc. announced it will appeal a first instance ruling by the Jinan Intermediate People's Court that restricts the use of certain systems for premolar extraction solutions in China. - The preliminary ruling is not yet legally effective and currently has no impact on clients or patients, while European and other Chinese courts have previously dismissed related claims against the company. - Angelalign maintains that its products do not infringe any valid patents and remains financially stable with a market capitalization of $2 billion USD.
06699+0.42%
Angelaligner Will Appeal Chinese Court Decision about Premolar Extraction Solution, Which Has No Impact on Customers
PR Newswire·Aug 13 at 03:52 AM
- Angelalign Technology Inc. announced it will appeal the August 10 first-instance judgment by the Jinan Intermediate People's Court regarding specific premolar extraction solutions. - The preliminary decision has not taken effect and currently has no impact on customers or patients in China. - The company maintains confidence that its A7 Premolar Extraction Solution does not infringe any valid patent.
06699+0.42%
Align Technology Wins China Patent Case Against Angelalign
rttnews·Aug 12 at 05:46 AM
- Align Technology won a patent infringement case in the Jinan Intermediate People's Court in China against Angelalign Technology's Chinese operating subsidiaries. - The court ruled that Angelalign infringed Align's patent rights through specific biomechanical simulation and digital orthodontic treatment design systems. - Angelalign was ordered to cease using the technology and infringing product operations, and was awarded RMB 10 million in damages.
ALGN+2.70%06699+0.42%
The Misfit Toys of Hong Kong Equities: Biotech Ambitions and Delisted Ghosts
Global Report·Aug 11 at 09:43 AM
- The article analyzes various Hong Kong stock assets, arguing that investors must distinguish between active innovative enterprises and stagnant traditional or defunct entities. - It highlights that companies like Everest Medicines and Bioland are actively advancing commercialization and product lines, while SaaS and traditional financial firms face shrinking spaces or lack growth narratives. - It concludes that market participants should direct capital only toward companies with substantive product delivery while abandoning outdated or delisted assets.
03661-3.21%06681-1.71%
Angelalign Posts Strong H1 Revenue, Profit
benzinga_article·Aug 6 at 02:06 PM
- Angelalign posted a 41.9% to 43.1% year-on-year revenue increase to between $229 million and $231 million, alongside a 69% to 78.9% profit jump in the first half of 2026. - The company's international sales volume reached 168,000 cases, surpassing its domestic sales volume of 148,600 cases during the same period. - These strong financial gains were driven by growing consumer awareness and successful global expansion, despite price pressures from China's national procurement program.
ALGN+2.70%06699+0.42%
Angelalign Technology hits 52-week high after profit alert
HK Stock Market Update·Aug 5 at 01:51 AM
06699+0.42%
Angelalign slips after hitting 52-week high on CICC target upgrade
HK Stock Market Update·Aug 5 at 01:47 AM
06699+0.42%